Pfizer Shares Weakly Respond to Strong Quarterly Report | R Blog RU


We haven’t talked about pharmaceutical companies producing vaccines against COVID-19 for a long time. And it seems in vain, because these organizations are now experiencing a real flourishing. Pfizer’s financial report for the first quarter of 2021 is the best confirmation of this. Let’s find out in more detail about the results of the first three months of this year.

Pfizer Q1 2021 Report

On May 4, the American pharmaceutical company released its quarterly report and boasted very impressive numbers. Vaccine revenue jumped 204%, according to published data.

It is important to note that sales of almost all products of this representative of the pharmaceutical market have grown. Revenue from the sale of drugs for the treatment of rare diseases in comparison with statistics for January-March 2020 increased by 29%, cancer – by 18%, immune diseases – by 9%.

Important data from the report

  • Revenue – $ 14.6 billion, + 45% (forecast – $ 13.54 billion).
  • Earnings per share – $ 0.93, + 47% (forecast – $ 0.76).
  • Net income – $ 4.9 billion, + 45%.
  • Revenue from anti-toxic vaccine – $ 3.5 billion (forecast – $ 2.2 billion).

Pfizer’s forecasts for the year

The pharmaceutical giant, given the strong statistics for January-March, changed its financial forecast for the year. The company now expects revenue for 2021 to reach $ 70.5-72.5 billion. Earlier it was predicted that this figure will be placed in the range from $ 59.4 to 61.4 billion. Adjusted earnings per share increased from $ 3.1- 3.2 to $ 3.55-3.65.

The annual income from the sale of an anti-toxic vaccine, developed in conjunction with the German BioNTech, was also revised – from $ 15 billion to $ 26 billion, which is an increase of 73%. Note that in the first quarter, the sale of this drug brought 24% of the total revenue. The pharmaceutical company expects to deliver 1.6 billion doses of the vaccine this year.

Pfizer Stock Technical Analysis

On May 3, the day before the Q1 2021 financial data was released, Pfizer (NYSE: PFE) rose 3.05% to $ 39.83. After the publication of the quarterly report, quotes rose only 0.3% to $ 39.95.

Here’s what my colleague, analyst Maxim Artyomov says about the future prospects for Pfizer shares:

“Against the backdrop of growth in revenue, the company’s shares, having completed the correction, began to recover their positions. On the daily chart, after the test of the support level, the quotes bounced and continue to grow within the boundaries of the ascending channel.

The stock is still trading above the 200-day moving average, which indicates that investors and speculators are interested in buying. Having updated the nearest maximum, the price will be able to continue the development of the upward trend.

The target for further growth is the all-time high of $ 42.6. If the maximum value is updated, the quotes may head to the $ 44 mark.

Summing up the result

Pfizer reported quarterly revenue and profit growth of 45%. Sales of the COVID-19 vaccine brought the pharmaceutical company $ 3.5 billion, up 59% from analysts’ forecasts.

Strong statistics for January-March gave the management of the concern to revise the forecast for this year. The size of the expected revenue increased to $ 70.5-72.5 billion, adjusted earnings per share – to $ 3.55–3.65, income from the sale of an anti-toxic vaccine – to $ 26 billion.

What else to read about pharmaceutical promotions on the R Blog?


Libertex [CPS] WW

xemarketsforex

xemarketsforex

MTP Procurement Management Procurement Bidding SRM Cost Optimization Team Management Cost Management SAP ERP Management Skills SAP ERP 1C Supply Control SAP / SRM SAP / R3 Analytical Thinking Working with Suppliers Result Oriented System Thinking Process Management Strategic Planning Project Management MsOffice Negotiations with company top officials Organization of procurement procedures Oil trading

Read Previous

Official exchange rate of the dollar and euro against the ruble as of May 6, 2021

Read Next

The confrontation between the SEC and Ripple continues: who will come out the winner?